[Federal Register Volume 70, Number 118 (Tuesday, June 21, 2005)]
[Notices]
[Pages 35683-35684]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-12108]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2003P-0501]


Determination That PYRIDOSTIGMINE BROMIDE Tablets, 30 Milligrams, 
Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) has determined that 
PYRIDOSTIGMINE BROMIDE tablets, 30 milligrams (mg), for the treatment 
of myasthenia gravis, were not withdrawn from sale for reasons of 
safety or effectiveness. This determination will allow FDA to approve 
abbreviated new drug applications (ANDAs) for PYRIDOSTIGMINE BROMIDE 
tablets, 30 mg, for the treatment of myasthenia gravis.

FOR FURTHER INFORMATION CONTACT: S. Mitchell Weitzman, Center for Drug 
Evaluation and Research (HFD-7), Food and Drug Administration, 5600 
Fishers Lane, Rockville, MD 20857, 301-443-5535.

SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price 
Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) 
(the 1984 amendments), which authorized the approval of duplicate 
versions of drug products approved under an ANDA procedure. ANDA 
sponsors must, with certain exceptions, show that the drug for which 
they are seeking approval contains the same active ingredient in the 
same strength and dosage form as the ``listed drug,'' which is 
typically a version of the drug that was previously approved under a 
new drug application (NDA). Sponsors of ANDAs do not have to repeat the 
extensive clinical testing otherwise

[[Page 35684]]

necessary to gain approval of an NDA. The only clinical data required 
in an ANDA are data to show that the drug that is the subject of the 
ANDA is bioequivalent to the listed drug.
    The 1984 amendments include what is now section 505(j)(7) of the 
Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(j)(7)), 
which requires FDA to publish a list of all approved drugs. FDA 
publishes this list as part of the ``Approved Drug Products with 
Therapeutic Equivalence Evaluations,'' which is generally known as the 
``Orange Book.'' Under FDA regulations in part 314 (21 CFR part 314), 
drugs are withdrawn from the list if the agency withdraws or suspends 
approval of the drug's NDA or ANDA for reasons of safety or 
effectiveness, or if FDA determines that the listed drug was withdrawn 
from sale for reasons of safety or effectiveness (Sec.  314.162).
    Under Sec.  314.161(a)(1), the agency must determine whether a 
listed drug was withdrawn from sale for reasons of safety or 
effectiveness before an ANDA that refers to that listed drug may be 
approved. FDA may not approve an ANDA that does not refer to a listed 
drug.
    PYRIDOSTIGMINE BROMIDE (mestinon) tablets (NDA 009-829), 60 mg, 
were originally approved on April 6, 1955, to treat myasthenia gravis. 
They were deemed effective under the Drug Efficacy Study Implementation 
on November 4, 1970 (35 FR 16992).
    A suitability petition was submitted under section 355(j)(2)(C) of 
the act and was approved for a change in strength for PYRIDOSTIGMINE 
BROMIDE (mestinon) tablets (i.e., from 60-mg tablets to 30-mg tablets) 
for the treatment of myasthenia gravis (see January 22, 1986, letter; 
Docket No. 1985P-0412). FDA approved ANDA 89-572, held by Solvay 
Pharmaceuticals, Inc., (Solvay), on November 27, 1990, for 
PYRIDOSTIGMINE BROMIDE tablets, 30 mg, for the treatment of myasthenia 
gravis. Solvay's PYRIDOSTIGMINE BROMIDE tablets, 30 mg, were 
discontinued from marketing on May 12, 1994, and at Solvay's request, 
approval of ANDA 89-572 was withdrawn effective August 11, 1994 (59 FR 
35527, July 12, 1994).
    On October 29, 2003, Lachman Consultant Services, Inc., submitted a 
citizen petition (Docket No. 2003P-0501) under 21 CFR 10.30 requesting 
that the agency determine whether PYRIDOSTIGMINE BROMIDE tablets, 30 
mg, for the treatment of myasthenia gravis, were withdrawn from sale 
for reasons of safety or effectiveness.
    The agency has determined that PYRIDOSTIGMINE BROMIDE tablets, 30 
mg, for the treatment of myasthenia gravis, were not withdrawn from 
sale for reasons of safety or effectiveness. The original basis for 
approving the suitability petition has not changed. PYRIDOSTIGMINE 
BROMIDE (mestinon) tablets, 60 mg, currently appear in the active 
section of the Orange Book. The agency notes that PYRIDOSTIGMINE 
BROMIDE (mestinon) tablets, 60 mg, are still being marketed by several 
other manufacturers (e.g., Impax Labs, Corepharma, and Barr). 
PYRIDOSTIGMINE BROMIDE (mestinon) syrup (NDA 15-193), 60 mg/5 
milliliters, also appears in the active section of the Orange Book. In 
approving the suitability petition, the agency noted that:

    [a]lthough the proposed strength is less than the currently 
approved product, the labeling of the currently approved products 
indicates that doses of 30 mg or even less may be utilized. 
Additionally, incremental doses are encouraged in approved labeling, 
especially ``for children and brittle myasthenic patients who 
require fractions of 60-mg doses''

(see Docket No. 1985P-0412). The currently available, relevant 
information does not call into question the agency's January 22, 1986, 
determination that ANDAs for PYRIDOSTIGMINE BROMIDE tablets, 30 mg, for 
the treatment of myasthenia gravis, are suitable for submission.
    The agency notes that PYRIDOSTIGMINE BROMIDE tablets, 30 mg, are 
also indicated for prophylaxis against the lethal effects of soman 
nerve agent poisoning, and are the subject of NDA 20-414. The U.S. Army 
submitted NDA 20-414, which was approved on February 5, 2003, under 
subpart I of the new drug regulations (Sec. Sec.  314.600 through 
314.650). NDA 20-414 is displayed in the ``Discontinued Drug Product 
List'' section of the Orange Book. Drug products approved for the U.S. 
Army are displayed in the discontinued section of the Orange Book 
because they are not commercially available. The agency notes that NDA 
20-414 is not the subject of this determination. The issue here is 
whether PYRIDOSTIGMINE BROMIDE tablets, 30 mg, for the treatment of 
myasthenia gravis (i.e., ANDA 89-572), were withdrawn from sale for 
reasons of safety or effectiveness.
    After considering the citizen petition and reviewing agency 
records, FDA determines that, for the reasons stated in this document, 
PYRIDOSTIGMINE BROMIDE tablets, 30 mg, were not withdrawn from sale for 
reasons of safety or effectiveness. Accordingly, the agency will 
continue to list PYRIDOSTIGMINE BROMIDE tablets, 30 mg, for the 
treatment of myasthenia gravis, in the ``Discontinued Drug Product 
List'' section of the Orange Book. ANDAs that refer to PYRIDOSTIGMINE 
BROMIDE tablets, 30 mg, for the treatment of myasthenia gravis, may be 
approved by the agency.

    Dated: June 14, 2005.
Jeffrey Shruen,
Assistant Commissioner for Policy.
[FR Doc. 05-12108 Filed 6-20-05; 8:45 am]
BILLING CODE 4160-01-S